Pharmaguy's Insights Into Drug Industry News
185.9K views | +17 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

Immunotherapy Drugs: A Chance to Live Longer or Die from Myriad Side Effects

Immunotherapy Drugs: A Chance to Live Longer or Die from Myriad Side Effects | Pharmaguy's Insights Into Drug Industry News | Scoop.it

So-called immunotherapy drugs [e.g., Opdivo, Yervoy, Ketruda] have been hailed as a breakthrough in cancer treatment, attracting billions of research dollars and offering new hope to patients out of options. But as their use grows, doctors are finding that they pose serious risks that stem from the very thing that makes them effective. An unleashed immune system can attack healthy, vital organs: notably the bowel, the liver and the lungs, but also the kidneys, the adrenal and pituitary glands, the pancreas and, in rare cases, the heart.

 

Doctors at Yale believe immunotherapy is causing a new type of acute-onset diabetes, with at least 17 cases there so far, Mr. Peal’s among them. In cancer clinics around the world, and in drug trials, myriad other side effects are showing up. Studies are finding that severe reactions occur nearly 20 percent of the time with certain drugs, and in more than half of patients when some drugs are used in combination.

 

Another recent paper found that 30 percent of patients experienced “interesting, rare or unexpected side effects,” with a quarter of the reactions described as severe, life-threatening or requiring hospitalization. Some patients have died, including five in recent months in clinical trials of a new immunotherapy drug being tested by Juno Therapeutics Inc.

 

“We are playing with fire,” said Dr. John Timmerman, an oncologist and immunotherapy researcher at the University of California, Los Angeles, who recently lost a patient to side effects. The woman’s immunotherapy drugs had successfully “melted away” her cancer, he said, but some weeks later, she got cold and flulike symptoms and died in the emergency room from an inflammatory response that Dr. Timmerman described as “a mass riot, an uprising” of her immune system.

 

“We’ve heard about immunotherapy as God’s gift, the chosen elixir, the cure for cancer,” he said. “We haven’t heard much about the collateral damage.”

 

Despite the warnings, physicians like Dr. Timmerman remain hugely supportive of drugs that are saving the lives of people who would otherwise die. Far better to cope with diabetes, hepatitis or arthritis, the thinking goes, than to die. Most reactions are not nearly so bad and are treatable.

 

The rub, doctors and researchers say, is that the medical system — from front-line nurses to oncologists to emergency rooms — is too often caught off guard. This is happening for a number of reasons: The drugs are new, so many side effects just have not been seen. Symptoms appear at random, sometimes months after treatment, and can initially seem innocuous. Finally, oncologists are now trying to treat patients with a combination of two or more immunotherapy drugs, hoping for more effective treatment but sometimes getting amplified risks.

 

In the meantime, these drugs are moving from academic centers into cancer clinics across the country, where oncologists in smaller cities most likely have less experience with the side effects.

 

And with lives to be saved and billions of dollars to be made — $250,000 or more is the list price for a year of some regimens — not enough research has been done into the risks of the new therapies, said William Murphy, a professor of dermatology at the University of California, Davis, who reviews immunotherapy-related grants for the government.

 

It is “a massively understudied area,” Dr. Murphy said, adding: “The No. 1 priority is anti-tumor effects. Everything else, however severe, is considered the price worth paying.”

Pharma Guy's insight:

Additional Reading:

  • “Opdivo TV Ads Educate Patients About the Positive, Not the Negative Trial Data;” http://sco.lt/5OtIdl
  • “Oncologists Say Cancer Drug Advertising Fosters Misinterpretation of Efficacy by Patients”; http://sco.lt/8Imgdd
  • “Opdivo Puts BMS Way Ahead in Revenue Generated by New Drug Sales”; http://sco.lt/5MWTVh
more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

AstraZeneca Sponsors Survey to Assess Patient Knowledge of Science Behind New Cancer Therapies

AstraZeneca Sponsors Survey to Assess Patient Knowledge of Science Behind New Cancer Therapies | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Today sees the release of the results of a May 2016 survey of patient/carer groups about patient-focused scientific information on cancer, sponsored by AstraZeneca. 

 

KEY FINDINGS FROM THE SURVEY INCLUDE:

 

  • 99% of respondent patient/carer organisations “Agree” or “Somewhat agree” that people living with cancer want to know how their cancer treatments work.
  • Over 90% of respondent patient/carer organisations “Agree” or “Somewhat agree” that patients must understand scientific concepts about cancer if they are to better manage their cancer.
  • 57% of respondents indicate that increasing the awareness of cancer treatment options among patients and the public is a top priority of their organisation.
  • 61% of respondents say that the public is unfamiliar with basic scientific concepts about cancer.
  • 83% of patient/carer organisations have been asked by patients/carers about immuno-oncology. However, only 48.2 % of those same organisations are themselves familiar with the topic of immunotherapies in oncology.
  • 67% of patient/carer organisations have been asked by patients/carers about gene mutations associated with cancer and biomarkers. Again, though, only 52 % of the organisations themselves claim familiarity with the concepts of genetic testing and precision medicine.
Pharma Guy's insight:

Immunotherapy may offer new hope to cancer patients, but is also creating new challenges by complicating clinical trial designsXconomy reports. Researchers worry patients who want access to a treatment in the headlines will sign up for a clinical trial but drop out if they are assigned to the control group. Patients in cancer drug trials often know whether they receiving an experimental drug or the control treatment, and blinding many studies is futile.

 

Tremelimumab has been one of AstraZeneca's top drug prospects and is a leading example of the kind of cancer programs the pharma giant hopes to use to generate billions of dollars in new sales. A setback here will raise fresh questions for AstraZeneca as it attempts to play catch-up to the market leaders in checkpoint inhibitors.

more...
No comment yet.